Zileuton
From Wikipedia, the free encyclopedia
| Image:Zileuton.png | |
| Image:Zileuton.gif | |
| Zileuton
| |
| Systematic (IUPAC) name | |
| 1-(1-benzothiophen-2-ylethyl)-1-hydroxy-urea | |
| Identifiers | |
| CAS number | 111406-87-2 |
| ATC code | ? |
| PubChem | 60490 |
| DrugBank | APRD00265 |
| Chemical data | |
| Formula | C11H12N2O2S |
| Mol. weight | 236.291 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Not yet established |
| Protein binding | 93% |
| Metabolism | Hepatic (CYP1A2, CYP2C9 and CYP3A4-mediated) |
| Half life | 2.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
℞-only(US) |
| Routes | Oral |
Zileuton (INN) is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.
Zileuton is marketed by Critical Therapeutics under the brand name Zyflo®.
[edit] External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
